AngioDynamics Inc Earnings: Beat on EPS with $0.02 vs -$0.11 Expected
AngioDynamics Inc (ANGO) delivered a significant earnings beat for the quarter ended April 2, 2026, reporting earnings per share of $0.02 versus analyst estimates of -$0.11, representing a positive surprise of 117.83%.
The medical device company’s actual EPS of $0.02 marked a substantial outperformance against the consensus estimate of -$0.11, with the 117.83% surprise indicating the company exceeded expectations by $0.13 per share.
Revenue came in at $78.42 million compared to estimates of $78.30 million, delivering a modest beat with a surprise of 0.15%. The revenue figure exceeded analyst projections by approximately $121,000.
The quarter’s results showed AngioDynamics achieving profitability against the anticipated loss of $0.11 per share—a remarkable turnaround that signals meaningful progress in the company’s ongoing transformation.
Company Background
AngioDynamics Inc is a medical device company specializing in minimally invasive, image-guided procedures for treating peripheral arterial disease, venous disorders, and various cancers. Headquartered in Latham, New York, the company’s product portfolio includes NanoKnife irreversible electroporation (IRE) systems for soft tissue ablation, thrombus management devices, and vascular access solutions. AngioDynamics serves hospitals and outpatient clinics globally and has been executing a multi-year transformation to concentrate on higher-growth, differentiated technology platforms.
Earnings Context and Transformation Progress
AngioDynamics has been divesting lower-margin commodity businesses to focus on its oncology and vascular access segments. The Q1 2026 earnings beat—turning an anticipated $0.11 loss into a $0.02 profit—suggests this restructuring is delivering real operational leverage. Analysts have been cautiously optimistic about the company’s NanoKnife platform, which holds promise for expanded oncology indications pending clinical trial outcomes. Revenue in-line performance at $78.42 million indicates stable underlying demand even as the company streamlines its business mix.
Outlook
With the restructuring phase largely complete, AngioDynamics is positioned to leverage its leaner cost structure for improved profitability going forward. Key watch items include NanoKnife regulatory progress, uptake of newer product introductions in vascular access, and whether the company can sustain this margin improvement over coming quarters. The strong EPS beat may prompt upward estimate revisions if management provides confidence in the durability of these results.
This article is for informational purposes only and does not constitute investment advice. Past performance does not guarantee future results.